RíoJNosCTintoréM. Defining the response to interferon-beta in relapsing–remitting multiple sclerosis patients. Ann Neurol2006; 59: 344–352.
2.
RudickRLeeJSimonJ. Defining interferon β response status in multiple sclerosis patients. Ann Neurol2004; 56: 548–555.
3.
RíoJCastillóJRoviraA. Measures in the first year of therapy predict the response to interferon beta in MS. Mult Scler2009; 15: 848–853.
4.
SormaniMPRioJTintorèM. Scoring treatment response in patients with relapsing multiple sclerosis. Mult Scler2013; 19: 605–612.
5.
SormaniMSignoriAStromilloM. Refining response to treatment as defined by the Modified Rio Score. Mult Scler2013; 19: 1246–1247.
6.
LublinFDReingoldSCCohenJA. Defining the clinical course of multiple sclerosis: The 2013 revisions. Neurology2014; 83: 278–286.
7.
SalzerJSvenningssonASundströmP. Neurofilament light as a prognostic marker in multiple sclerosis. Mult Scler2010; 16: 287–292.
8.
KuhleJPlattnerKBestwickJP. A comparative study of CSF neurofilament light and heavy chain protein in MS. Mult Scler J2013; 19: 1597–1603.
9.
TeunissenCEKhalilM. Neurofilaments as biomarkers in multiple sclerosis. Mult Scler J2012; 18: 552–556.
10.
GunnarssonMMalmeströmCAxelssonM. Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab. Ann Neurol2011; 69: 83–89.
11.
GnanapavanSHegenHKhalilM. Guidelines for uniform reporting of body fluid biomarker studies in neurologic disorders. Neurology2014; 83: 1210–1216.
12.
AxelssonMMalmeströmCGunnarssonM. Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis. Mult Scler J2014; 20: 43–50.
13.
KuhleJMalmeströmCAxelssonM. Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis. Acta Neurol Scand2013; 128: e33–36.
14.
TrentiniAComabellaMTintoréM. N-Acetylaspartate and neurofilaments as biomarkers of axonal damage in patients with progressive forms of multiple sclerosis. J Neurol2014; 261: 2338–2343.
